Early stage drug developer Charles River Laboratories is pushing further into Asia with its purchase of the microbiology subcontractor BRASS Pte Ltd. Terms of the acquisition were not disclosed.
CMC Biologics has received renewal of its GMP credentials from the Danish Medicines Agency (DKMA) after upgrading the manufacturing capacity at its Copenhagen site.
CDMO Particle Sciences has completed the manufacture of an intravaginal delivery device for anti-retrovirals that is designed to prevent the transmission of HIV.
Vetter says plans for a $100m (€74m) expansion are driven by continued growth in the biopharma industry and keep the firm one step “ahead of the curve.”
Lanxess backed enzyme and fine chemicals producer evocatal has moved to a new HQ, beefed up production capacity and is on the look out for new scientific staff.
Kiadis Pharma has called on the German Red Cross to make its candidate cancer treatment ahead of contractors with less experience of manufacturing blood-derived products.
AAIPharma says the merger with Cambridge Major Laboratories (CML) will bring clients the benefits of integrated Chemistry and Manufacturing Controls (CMC) services from two high-growth CMOs.
Investing in antibody-drug conjugates (ADCs) made sense despite CMO competition and the fact few of these hybrid drugs have been approved to date says Carbogen Amcis CEO, Mark Griffiths.
Beleaguered sterile injectables manufacturer Ben Venue Laboratories has announced it will close permanently by the end of 2013 and lay off 1,100 employees in Ohio.
Germany-based CMO CPM Contract Pharma was hit with the first US FDA warning letter for failing to self-identify its manufacturing facility and pay the facility fee required by the Generic Drug User Fee Amendments of 2012.
SCM Pharma says its ‘blank canvas’ manufacturing space fulfills evolving client development demands as the industry moves towards low-volume high-potency drugs.
Continued manufacturing problems at CMO Ben Venue Laboratories will cause an interruption of supplies of the cancer treatment Doxil in mid-to-late October, Janssen said.
In the wake of recent bribery scandals, Boehringer Ingelheim (B-I) has called for stricter regulations in China, as it plans to triple production at its Shanghai manufacturing site.
A collaboration to develop portable, flexible and continuous processing systems has the potential to transform oral solid dose (OSD) manufacturing, according to Pfizer, GEA and G-CON.
West has begun production at its second manufacturing facility in China, driven by the growing market for pharma injectable components in the Asia pacific region.
Pharma Technology Inc. (PTI) says its new deduster offers tablet manufacturers more flexibility with greater residual powder being removed due to its polymer spiral.
Molecular Profiles has been chosen to develop topical and solid dose formulations of a preclinical psoriasis treatment as part of a multicompany conglomerate led by Telormedix.
A federal judge in the Southern District of Ohio has approved a US FDA consent decree against Shamrock Medical Solutions for drug manufacturing and labeling violations.
Pfizer, GlaxoSmithKline, Sanofi, and at least ten other big pharma companies, CMOs and industry groups are criticizing aspects of the recent FDA draft guidance governing quality agreements.
Catalent Pharma Solutions has been named as the supplier of delayed-release technology for an epilepsy treatment launched by Supernus Pharmaceuticals in the US this month.
Aurobindo Pharma has given more details of a planned expansion of its API and antibiotics businesses and has confirmed its intention to rejig its injectables operations.
Knowing about manufacturing innovations as soon as possible is more important for BioPharmas than for their small molecule counterparts according to an MIT Professor interviewed by our new sister site BioPharma-Reporter.com
The CMO market remains highly fragmented with thirty percent of active players likely to exit the business in the next ten years, according to a Frost & Sullivan report.
GlaxoSmithKline is in talks with a number of companies interested in buying its Romanian manufacturing facility that was recently earmarked for closure.
